Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

Home

ADPT

A

Adaptive Biotechnologies Corporation (ADPT)

NMS – Цена в реальном времени. Валюта: USD

12.41

-1.55 (-11.10%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

12.65

+0.24 (1.93%)

После закрытия: Mar 27, 2026, 7:49 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year

Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year

An executive at Adaptive Biotechnologies reported the sale of 179,703 shares for about $2.37 million, based on a weighted average price of around $13.21 per share during March 11–13, 2026. This sale was executed directly and arose from the exercise and immediate sale of option-derived Common Stock; no indirect (e.g.

Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price

Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price

Francis Lo, Chief People Officer at Adaptive Biotechnologies (ADPT +0.00%), reported the sale of a combined 68,667 shares of common stock across two transactions in early March 2026, as disclosed in a pair of SEC Form 4 filings.

Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?

Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?

Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.23 per share a year ago.

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Видео

No Data

There is no data to display

Пресс-релизы

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024.

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced two non-exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage Adaptive's proprietary T-cell receptor (TCR) discovery capabilities and large-scale immune receptor antigen mapping data. Discovering disease-causing TCRs in rheumatoid arthritis Adaptive has identified autoreactive or ‘offender' TCRs that could potentially cause disease in patients with autoimmune indications.

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced Dr. Harlan Robins, Chief Scientific Officer and Co-Founder and Susan Bobulsky, Chief Commercial Officer, MRD will be participating in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology with deep dive into the clonoSEQ assay technology. The call will take place on Thursday, December 11, 2025, from 2:00 p.m. to 3:00 p.m. Eastern Time. Interested parties may reach out to their Jefferies sales representative for details.